Published • loading... • Updated
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
- South Korea's National Health Insurance Service approved reimbursement for XPOVIO® combined with bortezomib and dexamethasone to treat adult multiple myeloma patients after one prior therapy, effective March 1, 2026.
- XPOVIO® has three approved indications in South Korea for multiple myeloma and diffuse large B-cell lymphoma, with two indications included in the national reimbursement scheme.
- XPOVIO® is the world's first orally-available, selective XPO1 inhibitor and has national insurance coverage in five Asia-Pacific countries, including South Korea.
Insights by Ground AI
39 Articles
39 Articles
Coverage Details
Total News Sources39
Leaning Left3Leaning Right6Center16Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
12%
C 64%
R 24%
Factuality
To view factuality data please Upgrade to Premium
